S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Esperion Therapeutics Insider Trades

+0.09 (+1.17%)
(As of 11/26/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.30 million shs
Average Volume
848,835 shs
Market Capitalization
$226.22 million
P/E Ratio
Dividend Yield

Esperion Therapeutics (NASDAQ:ESPR) Insider Buying and Selling Activity

Insider Ownership

Number Of
Insiders Buying
(Last 12 Months)

Amount Of
Insider Buying
(Last 12 Months)
$4.07 M

Number Of
Insiders Selling
(Last 12 Months)

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get ESPR Insider Trade Alerts

Want to know when executives and insiders are buying or selling Esperion Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Esperion Therapeutics (NASDAQ ESPR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2021Target N V BiotechMajor ShareholderBuy200,000$20.37$4,074,000.004,377,964  
3/11/2020Timothy M MaylebenCEOBuy2,500$43.00$107,500.00111,998  
2/28/2020Timothy M MaylebenCEOBuy5,000$49.00$245,000.00109,498  
1/23/2020Target N V BiotechMajor ShareholderBuy20,000$51.84$1,036,800.003,747,964  
11/6/2019Target N V BiotechMajor ShareholderBuy75,000$37.30$2,797,500.003,727,964  
11/6/2019Timothy M MaylebenCEOBuy5,000$36.98$184,900.0083,663  
9/6/2019Timothy M MaylebenCEOBuy2,500$35.25$88,125.0076,015  
9/4/2019Target N V BiotechMajor ShareholderBuy80,000$33.78$2,702,400.003,652,964  
9/4/2019Timothy M MaylebenCEOBuy5,000$34.20$171,000.0076,015  
8/1/2019Timothy M MaylebenCEOBuy5,000$39.56$197,800.0071,163  
7/23/2019Target N V BiotechMajor ShareholderBuy50,000$42.65$2,132,500.003,572,964  
6/28/2019Timothy M MaylebenCEOBuy5,000$46.00$230,000.0066,163  
4/3/2019Richard BartramCFOSell8,000$42.88$343,040.00  
3/29/2019Timothy M MaylebenCEOBuy5,000$40.00$200,000.0061,163  
3/20/2019Timothy M MaylebenCEOBuy5,000$43.48$217,400.0056,163  
3/19/2019Nicole VitulloDirectorSell15,329$44.73$685,666.178,319  
3/14/2019Target N V BiotechMajor ShareholderBuy50,000$49.89$2,494,500.003,522,964  
3/14/2019Timothy M MaylebenCEOBuy5,000$48.73$243,650.0051,163  
3/12/2019Roger S NewtonDirectorSell25,000$50.06$1,251,500.00548,726  
1/4/2019Target N V BiotechMajor ShareholderBuy80,000$41.29$3,303,200.003,472,964  
12/24/2018Target N V BiotechMajor ShareholderBuy50,000$39.91$1,995,500.003,392,964  
12/17/2018Target N V BiotechMajor ShareholderBuy60,000$47.73$2,863,800.003,342,964  
11/5/2018Boxer Capital, LlcMajor ShareholderSell100,000$56.38$5,638,000.00  
11/2/2018Boxer Capital, LlcMajor ShareholderSell40,000$55.21$2,208,400.00  
11/2/2018Roger S NewtonDirectorSell2,827$50.07$141,547.89573,953  
10/18/2018Roger S NewtonDirectorSell100$50.00$5,000.00589,326  
10/16/2018Roger S NewtonDirectorSell9,400$50.01$470,094.00589,326  
8/27/2018Roger S NewtonDirectorSell17,700$51.05$903,585.00615,726  
8/17/2018Roger S NewtonDirectorSell7,300$50.06$365,438.00616,426  
8/3/2018Target N V BiotechMajor ShareholderBuy50,000$46.14$2,307,000.003,282,964  
7/12/2018Target N V BiotechMajor ShareholderBuy50,000$41.77$2,088,500.003,232,964  
6/29/2018Target N V BiotechMajor ShareholderBuy50,000$39.48$1,974,000.003,182,964  
6/21/2018Target N V BiotechMajor ShareholderBuy60,000$38.57$2,314,200.003,132,964  
6/7/2018Target N V BiotechMajor ShareholderBuy60,000$37.79$2,267,400.003,072,964  
6/5/2018Target N V BiotechMajor ShareholderBuy60,000$38.47$2,308,200.003,012,964  
5/21/2018Target N V BiotechMajor ShareholderBuy130,000$40.11$5,214,300.002,872,964  
5/18/2018Target N V BiotechMajor ShareholderBuy50,000$42.24$2,112,000.002,872,964  
3/29/2018Roger S NewtonDirectorSell25,000$72.37$1,809,250.00639,682  
1/25/2018Nicole VitulloDirectorSell11,674$71.79$838,076.463,177  
12/6/2017Nicole VitulloDirectorSell9,326$53.85$502,205.102,472  
3/22/2017Dov A Md GoldsteinDirectorSell800,000$41.66$33,328,000.00  
3/21/2017Gilbert S OmennDirectorBuy1,000$42.26$42,260.0010,000  
11/1/2016Narendra D LalwaniCOOBuy5,000$9.93$49,650.005,000  
7/6/2016Mark E McgovernDirectorBuy5,000$10.00$50,000.00600  
5/4/2016Timothy M MaylebenCEOBuy7,000$14.85$103,950.0041,614  
3/1/2016Gilbert S OmennDirectorBuy5,000$15.28$76,400.0010,000  
1/27/2016Timothy M MaylebenCEOBuy3,600$15.88$57,168.0034,614  
1/15/2016Timothy M MaylebenCEOBuy7,200$14.08$101,376.0031,014  
4/24/2015Dov A Md GoldsteinDirectorSell217,469$108.22$23,534,495.18  
11/18/2014Patrick G EnrightDirectorSell487,130$32.78$15,968,121.40  
10/21/2014Parters Vii L P DomainMajor ShareholderBuy500,000$20.00$10,000,000.00  
10/7/2014Longitude Capital Partners, LlMajor ShareholderSell11,927$30.04$358,287.08  
7/1/2013Brian H DoveyMajor ShareholderBuy285,714$14.00$3,999,996.00  
7/1/2013Daniel JanneyDirectorBuy235,714$14.00$3,299,996.00  
7/1/2013Roger S NewtonChairmanBuy42,346$14.00$592,844.00  
7/1/2013Timothy M MaylebenCEOBuy5,000$14.00$70,000.00  
(Data available from 1/1/2013 forward)

Esperion Therapeutics (NASDAQ:ESPR) Insider Trade Frequently Asked Questions

Who is on Esperion Therapeutics's Insider Roster?

The list of insiders at Esperion Therapeutics includes Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech, and Timothy M Mayleben.Learn more on ESPR's insiders

What percentage of Esperion Therapeutics stock is owned by insiders?

7.30% of Esperion Therapeutics stock is owned by insiders. Learn more on ESPR's insider holdings

Which Esperion Therapeutics insiders have been buying company stock?

The following insiders have purchased Esperion Therapeutics stock in the last 24 months: Target N V Biotech ($5,110,800.00), and Timothy M Mayleben ($352,500.00).

How much insider buying is happening at Esperion Therapeutics?

Insiders have purchased a total of 227,500 Esperion Therapeutics shares in the last 24 months for a total of $5,463,300.00 bought.

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.